Do Treatment Sequencing / Pathways Models Have a Place in Health Technology Appraisal?

Speaker(s)

Moderator: Hugo Pedder, PhD, MSc, BSc, Population Health Sciences, University of Bristol, Bristol, BST, UK
Panelists: Jeroen Jansen, PhD, Center for Translational and Policy Research on Precision Medicine, University of California – San Francisco, San Francisco, CA, USA; Dawn Lee, MMath, MSc, University of Exeter, Exeter, UK; Mark Harries, BPharm (Hons), MSc, MRPharmS, Market Access, Ipsen Ltd, London, LON, UK

Presentation Documents

ISSUE:

The panellists will debate the use of treatment sequence models (also called “pathways models”), using examples from oncology. They will discuss important challenges with developing these models, and whether the issues can be sufficiently addressed to support their implementation in HTA.

OVERVIEW:

Treatment sequence models are intended to evaluate the cost-effectiveness of a sequence of therapies that comprise a clinical pathway. This mitigates the issue of potentially inconsistent assumptions and recommendations that can arise from performing multiple single technology appraisals. However, there are numerous issues with their implementation both methodologically and logistically. Our issue panel will discuss these issues and how/whether they can be overcome, with perspectives from industry, HTA and academia:

  • The moderator (Dr Hugo Pedder, University of Bristol) will introduce the concept of treatment sequence models with an interactive example (10 minutes).
  • Dr Jeroen Jansen (University of California) will discuss methodological challenges and some of the lessons learned so far in his work on developing sequence models for the Innovation and Value Initiative (10 minutes).
  • Professor Dawn Lee (Peninsula Technology Assessment Group (PenTAG)) will discuss logistical challenges when implementing sequence models, including use of Real World Evidence and model validation, with experiences from a live NICE TA in advanced Renal Cell Carcinoma (aRCC) (10 minutes).
  • Mark Harries (Ipsen) will provide an industry perspective on the use of these models for HTA, with his experience representing the company in the NICE aRCC pilot pathway TA submission (10 minutes).
We will follow the discussion with a debate on whether such models can have a place in HTA, and if so, what form that should take (15-20 minutes).

Stakeholders working with HTAs or clinical guidelines may benefit from attending, whether from industry, public sector, or academia. Whilst we touch on technical details of economic modelling, the discussion will be of general interest.

Code

130

Topic

Health Technology Assessment